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OBJECTIVES: Attention-deﬁcit hyperactivity disorder (ADHD)
is a common disorder that is associated with broad functional
impairment among both children and adults. The purpose of this
project was to review literature on the economic costs of ADHD,
as well as potential economic beneﬁts of treating this condition.
METHODS: A literature search was performed using MEDLINE
to identify all published articles on the economic implications 
of ADHD, and authors were contacted to locate conference
abstracts and articles in press that were not yet indexed. In total,
22 relevant items were located including published original
studies, economic review articles, conference presentations, and
reports available on the Internet. RESULTS: Results of medical
cost studies consistently indicated that children with ADHD had
higher annual medical costs than either matched controls 
(difference ranged from $503 to $1343) or non-matched con-
trols (difference ranged from $207 to $1560) without ADHD.
Two studies of adult samples found similar results. A limited
number of studies have examined other economic implications
of ADHD including costs to families; costs of criminality among
individuals with ADHD; costs related to common psychiatric
and medical comorbidities of ADHD; and costs of accidents
among individuals with ADHD. Treatment cost-effectiveness
studies have primarily focused on methylphenidate, which is a
cost-effective treatment option with cost-effectiveness ratios
ranging from $15,509 to $27,766 per quality-adjusted life year
(QALY) gained. CONCLUSIONS: A growing body of literature,
primarily published in the United States, has demonstrated that
ADHD places a substantial economic burden on patients, fami-
lies, and third-party payers. Recognition, diagnosis and treat-
ment of ADHD are increasing in Europe and Australia, and
future studies may document the economic burden of ADHD in
these areas. As new treatments are introduced, it will be impor-
tant to evaluate their cost-effectiveness to provide an indication
of their potential value.
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OBJECTIVES: To develop a tool to allow estimation of the
budget impact of treatments for acute mania in bipolar I disor-
der from a US health care payer perspective. METHODS: Course
of each individual is simulated beginning with hospitalization.
Discharge depends on the level of symptoms as measured by the
Young Mania Rating Scale (YMRS). The effect of treatment is
determined using time-dependent regression equations derived
from trial data, and decision rules obtained from clinical experts.
Outcomes include: time to response and symptom resolution;
proportion of subjects reaching each outcome; number of
adverse events. Medical care costs were obtained from hospital
discharge databases, the National Medicare Physician Fee Sched-
ule and RedBook. Different scenarios are examined, each
describing the proportion of subjects on the various treatments
(lithium; divalproex sodium; olanzapine, risperidone and queti-
apine—monotherapy and in combination with lithium). The
base case scenario was derived from the distribution of treat-
ments observed in a state Medicaid population. Subjects may
switch treatment at any point, but analyses are intention-to-treat
over 100 days, corresponding to follow-up in mania trials.
RESULTS: Scenarios with a greater proportion of quetiapine
users (5% vs. 40% and 100%) result in a smaller impact on the
health care budget ($6912, $6277 and $5525 per patient, respec-
tively) and improvements in patient outcomes (e.g., 43%, 47%
and 54% responding at day 21; 74%, 77% and 80% remitting
by day 84). Quetiapine is cost-saving compared to olanzapine
(about $250 per patient), mainly due to fewer side-effects. Sen-
sitivity analyses showed the budget impact is inﬂuenced by drug
prices, discharge criteria and side-effect management. CON-
CLUSIONS: Results suggest that increased use of quetiapine for
mania in the US is economically sound and will improve health
outcomes. In addition, this model illustrates that discrete event
simulation is a very useful and versatile tool for budget impact
analyses.
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OBJECTIVE: To compare mental health-related costs among
patients with bipolar disorder treated with atypical antipsy-
chotics in a managed care setting. METHODS: This was a ret-
rospective cohort study using administrative claims data from a
national managed care organization. Participants initiated treat-
ment with risperidone, olanzapine, or quetiapine between July
1, 2000 and December 31, 2002, and had a bipolar disorder
diagnosis within six months of the index prescription for an
atypical antipsychotic. Subjects treated with more than one
antipsychotic at index were excluded. Subjects were matched one
to one on the propensity to receive risperidone using a score esti-
mated from a logistic regression model, which included age,
gender, psychiatric comorbidities, plan type, geographic region
and mood stabilizer use. Once matched, 12 months of follow-
up mental health-related costs and utilization data were com-
pared using univariate statistics. RESULTS: The olanzapine
cohort accounted for half of the study patients (n = 1660, 50%)
followed by the risperidone (n = 951, 29%) and quetiapine
cohorts (n = 699, 21%). After adjusting for treatment selection
bias through propensity matching, risperidone- and olanzapine-
treated subjects had similar mental health costs ($5728 vs.
$5908, respectively, NS). The cost of psychotropic therapy was
signiﬁcantly higher for the olanzapine versus risperidone cohort
($3363 vs. $2969, p = 0.001) and was the only signiﬁcant dif-
ference between these cohorts. Risperidone patients had signiﬁ-
cantly lower mental health costs compared to subjects treated
with quetiapine ($5666 vs. $6579, respectively, p = 0.007). Sub-
jects treated with risperidone also had signiﬁcantly lower psy-
chotropic therapy costs compared to quetiapine subjects ($2929
vs. $3492 respectively, p < 0.0001). CONCLUSION: In a
managed care setting, patients with bipolar disorder treated with
risperidone had similar mental health costs compared to patients
receiving olanzapine, and lower mental health costs compared to
those treated with quetiapine. This study provides important
comparative information on the real world cost of bipolar
patients treated with atypical antipsychotics.
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